First Tracks Biotherapeutics Inc(TRAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 4:28 PM ET (Korea 10/23 05:28)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 14.67% | Shs Outstand | 35.4M | Perf Week | 19.7% |
| Market Cap | 1.55B | Forward P/E | - | EPS next Y | 10.55% | Insider Trans | -0.74% | Shs Float | 30.6M | Perf Month | 17.68% |
| Enterprise Value | 1.39B | PEG | - | EPS next Q | -0.9 | Inst Own | 89.02% | Short Float | 16.94% | Perf Quarter | 21.45% |
| Income | - | P/S | - | EPS this Y | 26.72% | Inst Trans | 373.4% | Short Ratio | 6.05 | Perf Half Y | 127.05% |
| Sales | - | P/B | 9.04 | EPS next 5Y | 10.49% | ROA | - | Short Interest | 5.19M | Perf YTD | 115.7% |
| Book/sh | 4.77 | P/C | 9.22 | EPS past 3/5Y | - | ROE | - | 52W High | -13.57% ($49.91) | Perf Year | - |
| Cash/sh | 4.68 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 193.07% ($14.72) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 9.44% 9.38% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.28 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 64.7 | Recom | 1.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.28 | Sales Q/Q | - | SMA20 | 22.85% ($35.12) | Beta | - | Target Price | $74.17 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/12 | SMA50 | 11.19% ($38.8) | Rel Volume | 0.98 | Prev Close | $42.77 |
| Employees | - | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -18.37% - | SMA200 | 44.08% ($29.94) | Avg Volume(3M) | 0.86M | Price | $43.14 |
| IPO | 2026/4/6 | Option/Short | Yes/Yes | Trades | 8519 | Volume | 839,725 | Change | 0.87% |
� This is a clinical-stage biotech company developing antibody therapeutics that modulate immune pathways involved in autoimmune and inflammatory diseases. Its pipeline is centered on immune-modulating antibodies targeting celiac disease and eosinophilic esophagitis, along with a T-cell-targeting antibody aimed at rheumatoid arthritis, and the company is valued based on clinical progress rather than product revenue.
Over the past 1 year, on the higher side
14% below its 1-year high.
Traded about as much as usual. That is 98% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +26.7% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 89.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #124 of 594 in the industry
Based on market cap of $2B.
RARE#121 Ultragenyx Pharmaceutical Inc $2B PER - 
GPCR#122 Structure Therapeutics Inc ADR $2B PER - 
NTLA#123 Intellia Therapeutics Inc $2B PER - TRAX#124 First Tracks Biotherapeutics Inc $2B PER - 
KRSA#125 Korsana Biosciences Inc $2B PER - 
FAQ
What kind of company is TRAX?
TRAX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TRAX?
The market cap of TRAX is approximately $1.5B, ranking 2,268 within its sector.
What is the 52-week high and low for TRAX?
TRAX has recorded a 52-week high of $49.91 and a low of $14.72.
